Home / Market News / $ALGS
fiscal.ai Corporate Catalyst Impact 75/100 ● negative

Aligos Therapeutics Reports Q3 2026 Financial Results

Nov 6, 2026, 2:23 PM UTC · Primary ticker $ALGS

Aligos Therapeutics reported its Q3 2026 financial results, showing a narrowed operating loss and revenue from a collaboration agreement. The company's cash position of $31.1 million is expected to fund operations into Q1 2027, and it anticipates topline data for its B-SUPREME program in late Q3 2027. This filing provides an update on the company's financial health and a key upcoming clinical milestone.

Aligos Therapeutics (ALGS) reported its Q3 2026 financial results, which included a narrowed operating loss and revenue from a licensing agreement. The company's cash runway, extending into Q1 2027, is a critical short-term factor for biotech companies, indicating a need for future financing or significant progress. The anticipated topline data for the B-SUPREME program in late Q3 2027 represents a significant long-term catalyst or risk, as clinical trial results can dramatically impact a biotech's valuation. Traders will be watching for updates on the cash burn rate and the B-SUPREME data, which could lead to substantial price movements.

$ALGS neutral Primary subject of financial results and operational update
Source: fiscal.ai
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.